Spesolimab shows promise for Long-Term control of painful hand and foot pustules
NCT ID NCT04493424
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety of spesolimab for people with palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet. Participants who benefited from spesolimab in earlier trials can continue treatment for up to 5 years, with monthly injections and regular check-ups. The goal is to see if the drug remains safe and helps control symptoms over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- spesolimab
- What this could lead to
- If successful, this could show that spesolimab is safe and effective for long-term control of palmoplantar pustulosis, offering a treatment option for this chronic skin condition.
- What could go wrong
- This is a small, early-phase extension study that was terminated early, so results may be limited. Long-term safety and effectiveness are not yet proven, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asahikawa Medical University Hospital
Hokkaido, Asahikawa, 078-8510, Japan
-
Barbara Rewerska Diamond Clinic, Krakow
Krakow, 31-559, Poland
-
Brussels - UNIV Saint-Luc
Brussels, 1200, Belgium
-
CCBR Czech a.s.
Pardubice, 530 02, Czechia
-
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
-
Dermatovenereological Dispensary #10, St. Petersburg
Saint Petersburg, 194021, Russia
-
Dermmedica Sp. z o.o., Wroclaw
Wroclaw, 51-318, Poland
-
Dermoklinika medical center, Lodz
Lodz, 90-436, Poland
-
Dr. Irina Turchin PC Inc.
Fredericton, New Brunswick, E3B 1G9, Canada
-
Fujita Health University Hospital
Aichi, Toyoake, 470-1192, Japan
-
Fukuoka University Hospital
Fukuoka, Fukuoka, 814-0180, Japan
-
Gachon University Gil Medical Center
Incheon, 21565, South Korea
-
Gifu University Hospital
Gifu, Gifu, 501-1194, Japan
-
Guy's Hospital
London, SE1 9RT, United Kingdom
-
HOP Larrey
Toulouse, 31059, France
-
HOP Saint-Louis
Paris, 75010, France
-
HOP l'Archet
Nice, 06200, France
-
Independent Public Clin.Hosp.no1 Lublin
Lublin, 20-081, Poland
-
Innovaderm Research Inc.
Montreal, Quebec, H2X 2V1, Canada
-
Jichi Medical University Hospital
Tochigi, Shimotsuke, 329-0498, Japan
-
Kumamoto University Hospital
Kumamoto, Kumamoto, 860-8556, Japan
-
LLC "Medical Center Azbuka Zdorovia"
Kazan', 420111, Russia
-
Markusovszky University Teaching Hospital
Szombathely, 9700, Hungary
-
Menter Dermatology Research Institute
Dallas, Texas, 75246, United States
-
Municipal Hospital Complex in Olsztyn
Olsztyn, 10-229, Poland
-
Nakatsu Dermatology Clinic
Osaka, Osaka, 531-0071, Japan
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Nihon University Itabashi Hospital
Tokyo, Itabashi-ku, 173-8610, Japan
-
Okayama University Hospital
Okayama, Okayama, 700-8558, Japan
-
Osaka Metropolitan University Hospital
Osaka, Osaka, 545-8586, Japan
-
Osaka University Hospital
Osaka, Suita, 565-0871, Japan
-
Paratus Clinical Research Woden
Phillip, Australian Capital Territory, 2606, Australia
-
Royal Devon and Exeter Hospital
Exeter, EX2 5DW, United Kingdom
-
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
SBHI Chelyabinsk Reg.Clin.Derma.Dispen.
Chelyabinsk, 454048, Russia
-
Sagamihara National Hospital
Kanagawa, Sagamihara, 252-0392, Japan
-
Sanatorium Prof. Arenebergera
Prague, 11000, Czechia
-
Seoul National University Bundang Hospital
Seongnam, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Shiga University of Medical Science Hospital
Shiga, Otsu, 520-2192, Japan
-
Shinshu University Hospital
Nagano, Matsumoto, 390-8621, Japan
-
SimcoDerm Medical and Surgical Dermatology Centre
Barrie, Ontario, L4M 7G1, Canada
-
Skin Health Institute Inc
Carlton, Victoria, 3053, Australia
-
Takagi Dermatological Clinic
Hokkaido, Obihiro, 080-0013, Japan
-
Takamatsu Red Cross Hospital
Kagawa, Takamatsu, 760-0017, Japan
-
Teikyo University Hospital
Tokyo, Itabashi-ku, 173-8606, Japan
-
The Guenther Dermatology Research Centre
London, Ontario, N6A 3H7, Canada
-
The Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, 08520, United States
-
Tohoku University Hospital
Miyagi, Sendai, 980-8574, Japan
-
Tokyo Dental College Ichikawa General Hospital
Chiba, Ichikawa, 272-8513, Japan
-
Tokyo Medical University Hospital
Tokyo, Shinjuku-ku, 160-0023, Japan
-
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama, 35205, United States
-
UZ Leuven
Leuven, 3000, Belgium
-
Univ. Hospital Kralovske Vinohrady
Prague, 100 34, Czechia
-
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Kyoto, 602-8566, Japan
-
University of Missouri Health System
Columbia, Missouri, 65212, United States
-
University of Pecs
Pécs, 7632, Hungary
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Utah Health
Murray, Utah, 84107, United States
-
University of the Ryukyus Hospital
Okinawa, Nakagami-gun, 903-0215, Japan
-
Universitätsklinikum Erlangen
Erlangen, 91054, Germany
-
Universitätsklinikum Frankfurt
Frankfurt am Main, 60596, Germany
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, 24105, Germany
-
Wakayama Medical University Hospital
Wakayama, Wakayama, 641-8509, Japan
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug picankibart aims to treat stubborn hand and foot pustules
- Scientists seek skin samples to unlock secrets of common rashes
- New drug hope for painful hand and foot pustules
- AI boosts doctor accuracy for rare skin diseases in new study
- Promising drug for hand and foot blisters falls short in early trial
- New drug shows promise for painful hand and foot psoriasis